FIELD: pharmaceuticals.
SUBSTANCE: composition is characterized by that it contains a colloidal particle containing approximately 0.5 to 20 mol percent of amphiphilic lipid modified with a biocompatible hydrophilic polymer, wherein said coagulation factor is not encapsulated in said colloidal particle.
EFFECT: group of inventions discloses a pharmaceutical composition for subcutaneous administration containing a blood coagulation factor, as well as a method for preparing a pharmaceutical composition.
23 cl, 3 tbl, 2 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII | 2015 |
|
RU2721910C2 |
| IMPROVED FVIII FUSION PROTEIN AND ITS USE | 2019 |
|
RU2789085C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH CODES BLOOD COAGULATION FACTOR IX PROTEIN, AND USE THEREOF | 2021 |
|
RU2831751C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
| IMPROVED FACTOR IX FUNCTION PROTEIN AND ITS CONJUGATE AND THEIR USE | 2020 |
|
RU2794350C1 |
| COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS | 2021 |
|
RU2841237C1 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
